CLINICAL PHARMACOLOGY and THERAPEUTICS

Editor

Walter Modell, M.D.

Editorial Board

Alvito P. Alvares, Ph.D.
Wilbert S. Aronow, M.D.
Arthur J. Atkinson, Jr., M.D.
Daniel L. Azarnoff, M.D.
Frank M. Berger, M.D., D.Sc.
Karl H. Beyer, Jr., M.D., Ph.D.
Hylan A. Bickerman, M.D.
Edward A. Carr, Jr., M.D.
Leighton E. Cluff, M.D.
Allan H. Conney, Ph.D.
T. S. Danowski, M.D.
Arthur C. DeGraff, M.D.
Peter Dineen, M.D.
Edward F. Domino, M.D.
Alvan R. Feinstein, M.D.
Vladimir Fencl, M.D.
Max Fink, M.D.
Robert B. Forney, Ph.D.
Emil Frei, III, M.D.
Milo Gibaldi, Ph.D.
Norton J. Greenberger, M.D.
Franz Gross, M.D.
Arthur Hull Hayes, Jr., M.D.
Leo E. Hollister, M.D.
Bartholomet P. Hsi, Ph.D.
Murray E. Jarvik, M.D.
Ernest Jawetz, M.D., Ph.D.
Stanley A. Kaplan, Ph.D.
Attallah Kappas, M.D.
Arthur S. Keats, M.D.
Richard H. Kessler, M.D.
Kenneth G. Kohlstaedt, M.D.
Henn Kutt, M.D.
Louis Lasagna, M.D.
Louis Lemberger, M.D., Ph.D.
Gerhard Levy, Pharm.D.
T. A. Loomis, M.D., Ph.D.
David T. Lowenthal, M.D.
Daniel S. Lukas, M.D.
Dean T. Mason, M.D.
Arno G. Motulsky, M.D.
Marcus M. Reidenberg, M.D.
R. K. Richards, M.D.
David G. Shand, M.B., Ph.D.
Jay Tepperman, M.D.
Leroy D. Vandam, M.D.
Elliot S. Vesell, M.D.
Louis Weinstein, M.D.
John G. Wagner, Ph.D.
E. Leong Way, Ph.D.

Volume 26, June-December, 1979
The C. V. Mosby Company, St. Louis

Volume 26
Copyright © 1979 by
The C. V. Mosby Company

All rights reserved

Printed in the United States of America

Index to volume 26

Author index

A

Abel JG, Sellers EM, Naranjo CA, Shaw J, Kadar D, Romach MK: Inter- and intrasubject variation in diazepam free fraction, 247
Albert KS: *see* Garg et al, 232
Alberts DS, Chang SY, Chen H-SG, Moon TE, Evans TL, Furner RL, Himmelstein K, Gross JF: Kinetics of intravenous melphalan, 73
—, —, —, Evans TL, Moon TE: Oral melphalan kinetics, 737
Allen JP, Ludden TM, Burrow SR, Clementi WA, Stavchansky SA: Phenytoin cumulation kinetics, 445
Allen MD: *see* Greenblatt et al, 103
— *see* Ochs et al, 449
Alvares AP, Kappas A, Eiseman JL, Anderson KE, Pantuck CB, Pantuck EJ, Hsiao K-C, Garland WA, Conney AH: Intraindividual variation in drug disposition, 407
Anderson KE, Conney AH, Kappas A: Nutrition and oxidative drug metabolism in man; relative influence of dietary lipids, carbohydrate, and protein, 493
— *see* Alvares et al, 407
Anderson S: *see* Brater et al, 437
Andoh B: *see* Woolhouse et al, 584
Anttila M: *see* Sotaniemi et al, 153
Aoki FY, Sitar DS, Ogilvie RI: Amantadine kinetics in healthy young subjects after long-term dosing, 729
Appel GB: *see* Francke et al, 31, 228
Aristimuno GG: *see* Dreslinski et al, 562
Aronow WS, Landa D, Plasencia G, Wong R, Karlsberg RP, Ferlinz J: Verapamil in atrial fibrillation and atrial flutter, 578
Åsberg M: *see* Träskman et al, 600
Atkinson AJ Jr: *see* Stec et al, 618
Avakian EV, Horvath SM, Michael ED, Jacobs S: Effect of marihuana on cardiorespiratory responses to submaximal exercise, 777
Azarnoff DL: *see* Carruthers et al, 682
— *see* Cathcart-Rake et al, 89
Aziz NS: *see* Gambertoglio et al, 592

B

Barry KG: *see* Desjardins et al, 372
Barton N: *see* de Miranda et al, 718
Batra VK, Morrison JA, Lasseter KC, Joy VA: Piperacillin kinetics, 41
Bauer LA: *see* Blouin et al, 508
Beal S: *see* Sheiner et al, 294
Bechtold H: *see* Jähnchen et al, 187
— *see* Meinertz et al, 196
Becker KL: *see* Mohamadi and Bivins, 390
Bell RMS: *see* Winer et al, 315
Belleville JP, Dorey F, Bellville JW: Effects of nefopam on visual tracking, 457
Bellville JW: *see* Belleville et al, 457
Benet LZ: *see* Gambertoglio et al, 592
Bertilsson L, Braithwaite R, Tybring G, Garle M, Borgå O: Techniques for plasma protein binding of demethylchlorimipramine, 265
— *see* Träskman et al, 600
Bhat R: *see* Evans et al, 746
Bilezikian JP, Gammon DE, Rochester CL, Shand DG: A radioreceptor assay for propranolol, 173
Birkett DJ: *see* Grygiel et al, 660
Bivins L: *see* Mohamadi and Becker, 390
Bjornsson TD, Shand DG: Estimation of kinetic parameters from two-point determination of the drug cumulation factor, 540
Blouin RA, Mann HJ, Griffen WO Jr, Bauer LA, Record KE: Tobramycin pharmacokinetics in morbidly obese patients, 508
Blum MR: *see* de Miranda et al, 718
Bodem G: *see* Ochs et al, 449
Bodin NO: *see* Gram et al, 473
Bodison W: *see* Peitzman et al, 205
Boer P: *see* van Rooijen et al, 420
Bolme P: *see* Dahlström et al, 354
Boobis SW: *see* Trembath and Boobis, 654
Booker HE, Goodfriend TL, Tewksbury DA: Plasma renin concentration and phenobarbital levels in patients with epilepsy, 715
Booth RJ: *see* Wilson and Bullock, 209
Borg K-O: *see* Haglund et al, 326
Borgå O, Hoppel C, Odar-Cederlöf I, Garle M: Plasma levels and renal excretion of phenytoin and its metabolites in patients with renal failure, 306

July, pp. 1-144; August, pp. 145-274; September, pp. 275-406; October, pp. 407-536; November, pp. 537-668; December, pp. 669-800.

— *see* Bertilsson et al, 265
Bowdle TA, Levy RH, Cutler RE: Effects of carbamazepine on valproic acid kinetics in normal subjects, 629
Braithwaite R: *see* Bertilsson et al, 265
Branch RA: *see* Vestal et al, 8
— *see* Wood et al, 16
Brater C, Anderson S, Muckleroy C: Effects in normal subjects of long-term administration of azosemide, 437
Breimer DD: *see* de Boer et al, 701
Bressler R: *see* Dickerson et al, 502
Bullock JY: *see* Wilson and Booth, 209
Burrow SR: *see* Allen et al, 445

C

Caldwell J: *see* Monks et al, 513
Canfield CJ: *see* Desjardins et al, 372
Carruthers SG, Pentikainen P, Hosler JP, Azarnoff DL: Kinetics of pamatolol, cardioselective beta adrenoreceptor blocker, 682
Carter CH: *see* Winer et al, 315
Cathcart-Rake WF, Kyner JL, Azarnoff DL: Metabolic responses to plasma concentrations of theophylline, 89
Chabner BA: *see* Donehower et al, 63
Chan F-Y: *see* Kalow et al, 766
Chan KKH: *see* Miller et al, 54
Chang SY: *see* Alberts et al, 73, 737
Chen H-SG: *see* Alberts et al, 73, 737
Chew CYC, Collett J, Shah PK, Singh BN: Hemodynamic effects of intravenous timolol in coronary artery disease, 330
Chiariello M, Volpe M, Rengo F, Trimarco B, Violini R, Ricciardelli B, Condorelli M: Effect of furosemide on plasma concentration and β-blockade by propranolol, 433
Christian CD: *see* Dickerson et al, 502
Cleary T: *see* Kramer et al, 635
Clementi WA: *see* Allen et al, 445
Cocchetto DM: *see* de Miranda et al, 718
Cohen I: *see* Winer et al, 315
Cohen IM, O'Connor DT, Preston RA, Stone RA: Reduced renovascular resistance by clonidine, 572
Coleman MD: *see* Lake et al, 428
Collett J: *see* Chew et al, 330
Collste P: *see* Haglund et al, 326
Condorelli M: *see* Chiariello et al, 433
Conney AH: *see* Alvares et al, 407, 493
Conradi EC: *see* Walle et al, 167, 548, 686
Cooksley WGE: *see* Farrell et al, 483
Cronholm B: *see* Träskman et al, 600
Curtis GP: *see* Le Winter et al, 162
Cutler RE: *see* Bowdle et al, 629

D

Dahlström B, Bolme P, Feychting H, Noack G, Paalzow L: Morphine kinetics in children, 354
Davies DS: *see* FitzGerald et al, 669
Davis JM: *see* Pandey et al, 96
de Boer AG, Breimer DD, Mattie H, Pronk J, Gubbens-Stibbe JM: Rectal bioavailability of lidocaine in man; partial avoidance of "first-pass" metabolism, 701
del Greco F: *see* Stec et al, 618
de Miranda P, Whitley RJ, Blum MR, Keeney RE, Barton N, Cocchetto DM, Good S, Hemstreet GP III, Kirk LE, Page DA, Elion GB: Acyclovir kinetics after intravenous infusion, 718
Desjardins RE, Pamplin CL III, von Bredow J, Barry KG, Canfield CJ: Kinetics of new antimalarial, mefloquine, 372
Dickerson J, Bressler R, Christian CD, Hermann HW: Efficacy of estradiol vaginal cream in postmenopausal women, 502
DiStefano D: *see* Wiener et al, 696
Dollery CT: *see* FitzGerald et al, 669
Dominic J, McAllister RG Jr, Kuo C-S, Reddy CP, Surawicz B: Verapamil plasma levels and ventricular rate response in patients with atrial fibrillation and flutter, 710
Donehower RC, Hande KR, Drake JC, Chabner BA: Presence of 2,4-diamino-N^{10}-methylpteroic acid after high-dose methotrexate, 63
Dorey F: *see* Belleville et al, 457
Drake JC: *see* Donehower et al, 63
Dreslinski GR, Aristimuno GG, Messerli FH, Suarez DH, Frohlich ED: Effects of beta blockade with acebutolol on hypertension, hemodynamics, and fluid volume, 562
du Souich P, McLean AJ, Stoeckel K, Ohlendorf D, Gibaldi M: Screening methods using sulfamethazine for determining acetylator phenotype, 757

E

Eichelbaum M, Kothe KW, Hoffmann F, von Unruh GE: Kinetics and metabolism of carbamazepine during combined antiepileptic drug therapy, 366
Eidsaunet W: *see* Osnes et al, 399
Eiseman JL: *see* Alvares et al, 407
Elion GB: *see* de Miranda et al, 718
Ellis I: *see* Peitzman et al, 205
Endrenyi L: *see* Kalow et al, 766
Engler RL: *see* Le Winter et al, 162
Enjalbert M: *see* Larochelle et al, 24
Evans MA, Bhat R, Vidyasagar D, Vadapalli M, Fisher E, Hastreiter A: Gestational age and indomethacin elimination in the neonate, 746
Evans TL: *see* Alberts et al, 73, 737

F

Fagan TC: *see* Walle et al, 167, 548, 686
Fahmy NR, Malek NS, Lappas DG: Diazepam prevents some adverse effects of succinylcholine, 395

Farkas J: *see* Grygiel et al, 660
Farrell GC, Cooksley WGE, Powell LW: Drug metabolism in liver disease; activity of hepatic microsomal metabolizing enzymes, 483
Feinstein AR: Clinical biostatistics. XLVIII. Efficacy of different research structures in preventing bias in the analysis of causation, 129
— Clinical biostatistics. XLIX. The basic data structures used in quantitative indexes, 524
Ferlinz J: *see* Aronow et al, 578
Fernandez PC: *see* Peitzman et al, 205
Feychting H: *see* Dahlström et al, 354
Fischer C: *see* Klotz et al, 221
Fischer RP: *see* Miller et al, 54
Fisher E: *see* Evans et al, 746
FitzGerald GA, Hossmann V, Hamilton CA, Reid JL, Davies DS, Dollery CT: Interindividual variation in kinetics of infused epinephrine, 669
Franciosa JA, Johnson SM, Tobian LJ: Hemodynamic effects of oxprenolol and propranolol in hypertension, 676
Francke EL, Appel GB, Neu HC: Kinetics of intravenous amoxicillin in patients on long-term dialysis, 31
—, Mehta S, Neu HC, Appel GB: Kinetics of intravenous mezlocillin in chronic hemodialysis patients, 228
Frankel LS: *see* Kramer et al, 635
Friedman P: *see* Pfeifer et al, 36
Frisk-Holmberg M, Jorfeldt L, Juhlin-Dannfelt A, Karlsson J: Metabolic changes in muscle on long-term alprenolol therapy, 566
Frohlich ED: *see* Dreslinski et al, 562
Furner RL: *see* Alberts et al, 73
Furst DE, Tozer TN, Melmon KL: Salicylate clearance, the resultant of protein binding and metabolism, 380

G

Gaffney TE: *see* Walle et al, 167, 548, 686
Gambertoglio JG, Aziz NS, Lin ET, Grausz H, Naughton JL, Benet LZ: Cefamandole kinetics in uremic patients undergoing hemodialysis, 592
Gammon DE: *see* Bilezikian et al, 173
Garg DC, Wagner JG, Sakmar E, Weidler DJ, Albert KS: Rectal and oral absorption of methylprednisolone acetate, 232
Garland WA: *see* Alvares et al, 407
Garle M: *see* Bertilsson et al, 265
— *see* Borgå et al, 306
Geyskes GG: *see* van Rooijen et al, 420
Gibaldi M: *see* du Souich et al, 757
Gibson TP: *see* Stec et al, 618
Giles HG: *see* Sellers et al, 240
Goel I: *see* Pandey et al, 96
Good S: *see* de Miranda et al, 718
Goodfriend TL: *see* Booker et al, 715
Gram LF, Schou J, Way WL, Heltberg J, Bodin NO: *d*-Propoxyphene kinetics after single oral and intravenous doses in man, 473
Grausz H: *see* Gambertoglio et al, 592
Greenblatt DJ, Allen MD, Locniskar A, Harmatz JS, Shader RI: Lorazepam kinetics in the elderly, 103
— *see* Ochs et al, 449
— *see* Pfeifer et al, 36
— *see* Sellers et al, 240
Griesbach PH: *see* Rivera-Calimlim et al, 114
Griffen WO Jr: *see* Blouin et al, 508
Grindel JM, Migdalof BH, Plostnieks J: Absorption and excretion of tolmetin in arthritic patients, 122
Gross JF: *see* Alberts et al, 73
Grygiel JJ, Wing LMH, Farkas J, Birkett DJ: Effects of allopurinol on theophylline metabolism and clearance, 660
Gubbens-Stibbe JM: *see* de Boer et al, 701

H

Haglund K, Seideman P, Collste P, Borg K-O, von Bahr C: Influence of pentobarbital on metoprolol plasma levels, 326
Hamet P: *see* Larochelle et al, 24
Hamilton CA: *see* FitzGerald et al, 669
Hande KR: *see* Donehower et al, 63
Harland SJ: *see* Timbrell and Harland, 81
Harmatz JS: *see* Greenblatt et al, 103
— *see* Ochs et al, 449
Hastreiter A: *see* Evans et al, 746
Heltberg J: *see* Gram et al, 473
Hemstreet GP III: *see* de Miranda et al, 718
Hermann HW: *see* Dickerson et al, 502
Heykants J: *see* Jähnchen et al, 187
Himmelstein K: *see* Alberts et al, 73
Hoffmann F: *see* Eichelbaum et al, 366
Hoppel : *see* Borgå et al, 306
Horvath SM: *see* Avakian et al, 777
Hosler JP: *see* Carruthers et al, 682
Hossmann V: *see* FitzGerald et al, 669
Howell SB, Olshen RA, Rice JA: Effect of probenecid on cerebrospinal fluid methotrexate kinetics, 641
Hsiao K-C: *see* Alvares et al, 407
Humbert G: *see* Lecaillon et al, 611

I

Idle JR: *see* Woolhouse et al, 584
Illett KF, Madsen BW, Woods JD: Disopyramide kinetics in patients with acute myocardial infarction, 1
Ingelfinger JA: *see* Woods and Ingelfinger, 21
Ivanovich P: *see* Stec et al, 618

J

Jacobs S: *see* Avakian et al, 777

Jähnchen E, Bechtold H, Kasper W, Kersting F, Just H, Heykants J, Meinertz T: Lorcainide; saturable presystemic elimination, 187
— *see* Meinertz et al, 196
Järvensivu P: *see* Sotaniemi et al, 153
Johnson SM: *see* Franciosa et al, 676
Jorfeldt L: *see* Frisk-Holmberg et al, 566
Joy VA: *see* Batra et al, 41
Juhlin-Dannfelt A: *see* Frisk-Holmberg et al, 566
Just H: *see* Jähnchen et al, 187
— *see* Meinertz et al, 196

K

Kadar D: *see* Abel et al, 247
— *see* Kalow et al, 766
Kalow W, Tang BK, Kadar D, Endrenyi L, Chan F-Y: Method for studying drug metabolism in populations; racial differences in amobarbital metabolism, 766
Kaplan H: *see* Sellers et al, 240
Kappas A: *see* Alvares et al, 407
— *see* Anderson et al, 493
Kapur BM: *see* Martin et al, 256
Karlsberg RP: *see* Aronow et al, 578
Karlsson J: *see* Frisk-Holmberg et al, 566
Kasper W: *see* Jähnchen et al, 187
— *see* Meinertz et al, 196
Keeney RE: *see* de Miranda et al, 718
Kersting F: *see* Jähnchen et al, 187
— *see* Meinertz et al, 196
Kirk LE: *see* de Miranda et al, 718
Klotz U, Fischer C, Müller-Seydlitz P, Schulz J, Müller WA: Alterations in the disposition of differently cleared drugs in patients with cirrhosis, 221
Knapp DR: *see* Kuhnert et al, 213
Kochak GM: *see* Winer et al, 315
Kohl S: *see* Kramer et al, 635
Kopin IJ: *see* Lake et al, 428, 647
Kothe KW: *see* Eichelbaum et al, 366
Kramer WG, Cleary T, Frankel LS, Kohl S, Pickering K: Multiple-dose amikacin kinetics in pediatric oncology patients, 635
Kuhnert BR, Knapp DR, Kuhnert PM, Prochaska AL: Maternal, fetal, and neonatal metabolism of lidocaine, 213
Kuhnert PM: *see* Kuhnert et al, 213
Kuo C-S: *see* Dominic et al, 710
Kupersmith J: *see* Wiener et al, 696
Kyner JL: *see* Cathcart-Rake et al, 89

L

Lake CR, Ziegler MG, Coleman MD, Kopin IJ: Hydrochlorothiazide-induced sympathetic hyperactivity in hypertensive patients, 428
—, Mikkelsen EJ, Rapoport JL, Zavadil AP III, Kopin IJ: Effect of imipramine on norepinephrine and blood pressure in enuretic boys, 647
Landa D: *see* Aronow et al, 578
Lappas DG: *see* Fahmy and Malek, 395
Larochelle P, Hamet P, Enjalbert M: Responses to tyramine and norepinephrine after imipramine and trazodone, 24
Larsen S: *see* Osnes et al, 399
Lasseter KC: *see* Batra et al, 41
Lecaillon JB, Souppart C, Schoeller J, Humbert G, Massias P: Sulfinpyrazone kinetics after intravenous and oral administration, 611
Lespier-Dexter LE, Martinez-Maldonado M: Changes in calcium excretion after prolonged metolazone therapy in recurrent stone formers, 752
Levy RH: *see* Bowdle et al, 629
Le Winter MM, Curtis GP, Engler RL, Shabetai R, Verba J: Effects of equiblocking doses of nadolol and propranolol on left ventricular performance, 162
Lin ET: *see* Gambertoglio et al, 592
Lindsay WG: *see* Miller et al, 54
Locniskar A: *see* Greenblatt et al, 103
Ludden TM: *see* Allen et al, 445

M

MacLeod SM: *see* Sellers et al, 240
Madsen BW: *see* Illett et al, 1
Mahgoub A: *see* Woolhouse et al, 584
Malek NS: *see* Fahmy and Lappas, 395
Mann HJ: *see* Blouin et al, 508
Marathe VV: *see* Sheiner et al, 294
Maronde RF: *see* Velasquez et al, 555
Martin PR, Kapur BM, Whiteside EA, Sellers EM: Intravenous phenobarbital therapy in barbiturate and other hypnosedative withdrawal reactions; kinetic approach, 256
Martinez-Maldonado LE: *see* Lespier-Dexter and Martinez-Maldonado, 752
Mason WD: *see* Winer et al, 315
Massias P: *see* Lecaillon et al, 611
Mattie H: *see* de Boer et al, 701
McAllister RG Jr: *see* Dominic et al, 710
McCoy HG: *see* Miller et al, 54
McLean AJ: *see* du Souich et al, 757
Mees EJD: *see* van Rooijen et al, 420
Mehta S: *see* Francke et al, 228
Meinertz T, Kasper W, Kersting F, Just H, Bechtold H, Jähnchen E: Lorcainide; plasma concentration-effect relationship, 196
— *see* Jähnchen et al, 187
Mellström B: *see* Träskman et al, 600
Melmon KL: *see* Furst and Tozer, 380
Messerli FH: *see* Dreslinski et al, 562
Michael ED: *see* Avakian et al, 777
Migdalof BH: *see* Grindel et al, 122
Mikkelsen E: *see* Pedersen, 339
Mikkelsen EJ: *see* Lake et al, 647
Miller KW, Chan KKH, McCoy HG, Fischer RP, Lindsay WG, Zaske DE: Cephalothin kinetics; before, during and after cardiopulmonary bypass surgery, 54

Mindich B: *see* Wiener et al, 696
Mohamadi M, Bivins L, Becker KL: Effect of thiazides on serum calcium, 390
Monks TJ, Caldwell J, Smith RL: Influence of methylxanthine-containing foods on theophylline metabolism and kinetics, 513
Moon TE: *see* Alberts et al, 73, 37
Morrison JA: *see* Batra et al, 41
Muckleroy C: *see* Brater et al, 437
Müller WA: *see* Klotz et al, 221
Müller-Seydlitz P: *see* Klotz et al, 221

N

Naranjo CA: *see* Abel et al, 247
— *see* Sellers et al, 240
Naughton JL: *see* Gambertoglio et al, 592
Neckers LM: *see* Träskman et al, 600
Neu HC: *see* Francke et al, 31, 228
Nevin MJ: *see* Stec et al, 618
Noack G: *see* Dahlström et al, 354

O

Ochs HR, Greenblatt DJ, Allen MD, Harmatz JS, Shader RI, Bodem G: Effect of age and Billroth gastrectomy on absorption of desmethyldiazepam from clorazepate, 449
O'Connor DT: *see* Cohen et al, 572
Odar-Cederlöf I: *see* Borgå et al, 306
Ogilvie RI: *see* Aoki et al, 729
Ollendorf D: *see* du Souich et al, 757
Olshen RA: *see* Howell et al, 641
Osnes M, Larsen S, Eidsaunet W, Thom E: Effect of diclofenac and naproxen on gastroduodenal mucosa, 399

P

Paalzow L: *see* Dahlström et al, 354
Page DA: *see* de Miranda et al, 718
Pamplin CL III: *see* Desjardins et al, 372
Pandey GN, Goel I, Davis JM: Effect of neuroleptic drugs on lithium uptake by the human erythrocyte, 96
Pantuck CB: *see* Alvares et al, 407
Pantuck EJ: *see* Alvares et al, 407
Passananti GT: *see* Vesell and Shively, 287
Pazmĩno P, Rogoff F, Weinshilboum R: Inhibition of human erythrocyte phenol-O-methyltransferase in uremia, 464
Peck V, Shenkman L: Haloperidol-induced syndrome of inappropriate secretion of antidiuretic hormone, 442
Pedersen OL, Mikkelsen E: Serum potassium and uric acid changes during treatment with timolol alone and in combination with a diuretic, 339
Peitzman SJ, Fernandez PC, Bodison W, Ellis I: Ticrynafen and probenecid in hyperuricemic, hypertensive men, 205
Pelkonen RO: *see* Sotaniemi et al, 153
Pentikainen P: *see* Carruthers et al, 682
Perlmutter R: *see* Rivera-Calimlim et al, 114
Pfeifer HJ, Greenblatt DJ, Friedman P: Effects of three antibiotics on theophylline kinetics, 36
Pickering LK: *see* Kramer et al, 635
Plasencia G: *see* Aronow et al, 578
Plostnieks J: *see* Grindel et al, 122
Powell LW: *see* Farrell et al, 483
Preston RA: *see* Cohen et al, 572
Prochaska AL: *see* Kuhnert et al, 213
Pronk J: *see* de Boer et al, 701

R

Rapoport JL: *see* Lake et al, 647
Record KE: *see* Blouin et al, 508
Reddy CP: *see* Dominic et al, 710
Reid JL: *see* FitzGerald et al, 669
Rengo F: *see* Chiariello et al, 433
Ricciardelli B: *see* Chiariello et al, 433
Rice JA: *see* Howell et al, 641
Rivera-Calimlim L, Griesbach PH, Perlmutter R: Plasma chlorpromazine concentrations in children with behavioral disorders and mental illness, 114
Rochester CL: *see* Bilezikian et al, 173
Rogoff F: *see* Pazmĩno et al, 464
Romach MK: *see* Abel et al, 247
Rosenberg B: *see* Sheiner et al, 294
Rothschild BM: Hematologic perturbations associated with salicylate, 145
Ruo TI: *see* Stec et al, 618

S

Sakmar E: *see* Garg et al, 232
Schoeller J-P: *see* Lecaillon et al, 611
Schou J: *see* Gram et al, 473
Schulz J: *see* Klotz et al, 221
Seideman P: *see* Haglund et al, 326
Sellers EM, Greenblatt DJ, Giles HG, Naranjo CA, Kaplan H, MacLeod SM: Chlordiazepoxide and oxazepam disposition in cirrhosis, 240
— *see* Abel et al, 247
— *see* Martin et al, 256
Shabetai R: *see* LeWinter et al, 162
Shader RI: *see* Greenblatt et al, 103
— *see* Ochs et al, 449
Shah PK: *see* Chew et al, 330
Shand DG: *see* Bilezikian et al, 173
— *see* Bjornsson and Shand, 540
— *see* Vestal et al, 8
— *see* Vestal and Wood, 181
— *see* Wood et al, 16
Shaw J: *see* Abel et al, 247
Sheiner LB, Beal S, Rosenberg B, Marathe VV: Forecasting individual pharmacokinetics, 294
Shenkman L: *see* Peck and Shenkman, 442
Shively CA: *see* Vesell and Passananti, 287
Sicé J: How much is enough? 537

Singh BN: *see* Chew et al, 330
Sitar DS: *see* Aoki et al, 729
Sjöqvist F: *see* Träskman et al, 600
Sloan TP: *see* Woolhouse et al, 584
Smith RL: *see* Monks et al, 513
— *see* Woolhouse et al, 584
Sommers DK: Reactivity of cardiovascular system in tetraplegic patient, 344
Sotaniemi EA, Anttila M, Pelkonen RO, Järvensivu P, Sundquist H: Plasma clearance of propranolol and sotalol and hepatic drug-metabolizing enzyme activity, 153
Souppart C: *see* Lecaillon et al, 611
Stavchansky SA: *see* Allen et al, 445
Stec GP, Atkinson AJ Jr, Nevin MJ, Thenot J-P, Ruo TI, Gibson TP, Ivanovich P, del Greco F: *N*-Acetylprocainamide pharmacokinetics in functionally anephric patients before and after perturbation by hemodialysis, 618
Stoeckel K: *see* du Souich et al, 757
Stone RA: *see* Cohen et al, 572
Suarez DH: *see* Dreslinski et al, 562
Sundquist H: *see* Sotaniemi et al, 153
Surawicz B: *see* Dominic et al, 710

T

Tang BK: *see* Kalow et al, 766
Tewksbury DA: *see* Booker et al, 715
Thenot J-P: *see* Stec et al, 618
Thom E: *see* Osnes et al, 399
Thorén P: *see* Träskman et al, 600
Timbrell JA, Harland SJ: Identification and quantitation of hydrazine in urine of patients treated with hydralazine, 81
Tobian LJ: *see* Franciosa et al, 676
Tozer TN: *see* Furst and Melmon, 380
Träskman L, Åsberg M, Bertilsson L, Cronholm B, Mellström B, Neckers LM, Sjöqvist F, Thorén P, Tybring G: Plasma levels of chlorimipramine and its demethyl metabolite during treatment of depression, 600
Trembath PW, Boobis SW: Plasma theophylline levels after sustained-release aminophylline, 654
Trimarco B: *see* Chiariello et al, 433
Tybring G: *see* Bertilsson et al, 265
— *see* Träskman et al, 600

V

Vadapalli M: *see* Evans et al, 746
van Rooijen GJM, Boer P, Mees EJD, Geyskes GG: Effects of atenolol and propranolol when added to long-term antihypertensive diuretic therapy, 420
Velasquez MT, Wan SH, Maronde RF: Effects of metoprolol on blood pressure and plasma renin activity in thiazide-resistant hypertensive patients, 555
Verba J: *see* Le Winter et al, 162
Vesell ES: The antipyrine test in clinical pharmacology; conceptions and misconceptions, 275
—, Shively CA, Passananti GT: Failure of cola nut chewing to alter antipyrine disposition in normal male subjects from small town in South Central Pennsylvania, 287
Vestal RE, Wood AJJ, Branch RA, Shand DG, Wilkinson GR: Effects of age and cigarette smoking on propranolol disposition, 8
—, —, Shand DG: Reduced β-adrenoreceptor sensitivity in the elderly, 181
— *see* Wood et al, 16
Vidyasagar D: *see* Evans et al, 746
Violini R: *see* Chiariello et al, 433
Volpe M: *see* Chiariello et al, 433
von Bahr C: *see* Haglund et al, 326
von Bredow J: *see* Desjardins et al, 372
von Unruh GE: *see* Eichelbaum et al, 366

W

Wagner JG: *see* Garg et al, 232
Walle T, Conradi EC, Walle UK, Fagan TC, Gaffney TE: Naphthoxylactic acid after single and long-term doses of propranolol, 548
—, —, —, —,— Propranolol glucuronide cumulation during long-term propranolol therapy; proposed storage mechanism for propranolol, 686
—, Fagan TC, Conradi EC, Walle UK, Gaffney TE: Presystemic and systemic glucuronidation of propranolol, 167
Walle UK: *see* Walle et al, 167, 548, 686
Wan SH: *see* Velasquez et al, 555
Way WL: *see* Gram et al, 473
Weidler DJ: *see* Garg et al, 232
Weinshilboum R: *see* Pazmiño et al, 464
Whiteside EA: *see* Martin et al, 256
Whitley RJ: *see* de Miranda et al, 718
Wiener I, Mindich B, DiStefano D, Kupersmith J: Regional effects of propranolol in intraventricular conduction in coronary artery disease, 696
Wilkinson GR: *see* Vestal et al, 8
— *see* Wood et al, 16
Willoughby TL: *see* Winer et al, 315
Wilson JD, Bullock JY, Booth RJ: Influence of prazosin on the development of antinuclear antibodies in hypertensive patients, 209
Winer N, Mason WD, Carter CH, Willoughby TL, Kochak GM, Cohen I, Bell RMS: Effects of atenolol on blood pressure, heart rate, renin, and norepinephrine during exercise, 315
Wing LMH: *see* Grygiel et al, 660
Wong R: *see* Aronow et al, 578

Wood AJJ, Vestal RE, Wilkinson GR, Branch RA, Shand DG: Effect of aging and cigarette smoking on antipyrine and indocyanine green elimination, 16
— *see* Vestal et al, 8
— *see* Vestal and Shand, 181
Woods JD: *see* Illett et al, 1
Woods MN, Ingelfinger JA: Lack of effect of bran on digoxin absorption, 21
Woolhouse NM, Andoh B, Mahgoub A, Sloan TP, Idle JR, Smith RL: Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians, 584

Z

Zaske DE: *see* Miller et al, 54
Zavadil AP III: *see* Lake et al, 647
Ziegler MG: *see* Lake et al, 428

Subject index

A

Absorption, rectal and oral, of methylprednisolone acetate (Garg et al), 232
Acebutolol, beta blockade with, effects of, on hypertension, hemodynamics, and fluid volume (Dreslinski et al), 562
Acetylator phenotype, screening methods using sulfamethazine for determining (du Souich et al), 757
N-Acetylprocainamide kinetics in functionally anephric patients before and after perturbation by hemodialysis (Stec et al), 618
Acyclovir kinetics after intravenous infusion (de Miranda et al), 718
Adverse effects of succinylcholine prevented by diazepam (Fahmy et al), 395
Age and Billroth gastrectomy, effect of, on absorption of desmethyldiazepam from clorazepate (Ochs et al), 449
and cigarette smoking, effect of, on antipyrine and indocyanine green elimination (Wood et al), 16
on propranolol disposition (Vestal et al), 8
Agonist and antagonist drugs, diminished beta adrenergic response to, with age (Vestal et al), 181
Allopurinol, effects of, on theophylline metabolism and clearance (Grygiel et al), 660
Alprenolol therapy, long-term, metabolic changes in muscle on (Frisk-Holmberg et al), 566
Amantadine kinetics in healthy young subjects after long-term dosing (Aoki et al), 729
American Society for Clinical Pharmacology and Therapeutics, notes of, 142, 272, 535, 782
Amikacin, multiple-dose, kinetics in pediatric oncology patients (Kramer et al), 635
Aminophylline, sustained-release, plasma theophylline levels after (Trembath et al), 654
Amobarbital metabolism, racial differences in; method for studying drug metabolism in populations (Kalow et al), 766
Amoxicillin, intravenous, kinetics of, in patients on long-term dialysis (Francke et al), 31
Anephric patients, functionally, *N*-acetylprocainamide kinetics in, before and after hemodialysis (Stec et al), 618
Announcements, 274
Antibiotics, three, effects of, on theophylline kinetics (Pfeifer et al), 36
Antinuclear antibodies, development of, influence of prazosin on, in hypertensive patients (Wilson et al), 209
Antipyrine disposition, failure of cola nut chewing to alter, in normal male subjects from small town in South Central Pennsylvania (Vesell et al), 287
and indocyanine green elimination, effect of aging and cigarette smoking on (Wood et al), 16
test in clinical pharmacology; conceptions and misconceptions (Vesell), 275 (Commentary)
Arthritic patients, absorption and excretion of tolmetin in (Grindel et al), 122
Aspirin, adverse hematologic effects induced by (Rothschild), 145 (Commentary)
Assay, radioreceptor, for propranolol (Bilezikian et al), 173
Atenolol, effects of, on blood pressure, heart rate, renin, and norepinephrine during exercise (Winer et al), 315
and propranolol, effects of, when added to long-term antihypertensive diuretic therapy (van Rooijen et al), 420
Atrial fibrillation and flutter, verapamil in (Aronow et al), 578
plasma levels and ventricular rate response in patients with (Dominic et al), 710
Azosemide, long-term administration of, effects of, in normal subjects (Brater et al), 437

B

Barbiturate and other hypnosedative withdrawal reactions, intravenous phenobarbital therapy in; kinetic approach (Martin et al), 256
Behavioral disorders and mental illness, children with, plasma chlorpromazine concentrations in (Rivera-Calimlim et al), 114

July, pp. 1-144; August, pp. 145-274; September, pp. 275-406; October, pp. 407-536; November, pp. 537-668; December, pp. 669-800.

Beta adrenoreceptor blocker, cardioselective; kinetics of pamatolol (Carruthers et al), 682
sensitivity, reduced, in elderly (Vestal et al), 181
blockade with acebutolol, effects of, on hypertension, hemodynamics, and fluid volume (Dreslinski et al), 562
plasma concentration and, by propranolol, effect of furosemide on (Chiariello et al), 433
Bias, preventing, in analysis of causation, efficacy of different research structures in (Feinstein), 129 (Clinical biostatistics)
Billroth gastrectomy and age, effect of, on absorption of desmethyldiazepam from clorazepate (Ochs et al), 449
Bioavailability of methylprednisolone acetate (Garg et al), 232
propranolol, glucuronidation as determinant of (Walle et al), 167
rectal, of lidocaine in man; partial avoidance of "first-pass" metabolism (de Boer et al), 701
Biostatistics, clinical. XLVIII. Efficacy of different research structures in preventing bias in analysis of causation (Feinstein), 129
XLIX. Basic data structures used in quantitative indexes (Feinstein), 524
Blood pressure, heart rate, renin, and norepinephrine, effects of atenolol on, during exercise (Winer et al), 315
and norepinephrine in enuretic boys, effect of imipramine on (Lake et al), 647
and plasma renin activity, effects of metoprolol on, in thiazide-resistant hypertensive patients (Velasquez et al), 555
Books received, 274, 406, 536, 668
Bran, lack of effect of, on digoxin absorption (Woods and Ingelfinger), 21

C

Calcium excretion, changes in, after prolonged metolazone therapy in recurrent stone formers (Lespier-Dexter and Martinez-Maldonado), 752
serum, effect of thiazides on (Mohamadi et al), 390
Carbamazepine, effects of, on valproic acid kinetics in normal subjects (Bowdle et al), 629
kinetics and metabolism of, during combined antiepileptic drug therapy (Eichelbaum et al), 366
Carbohydrate, lipids, and protein, dietary, relative influence of; nutrition and oxidative drug metabolism in man (Anderson et al), 493
Cardiopulmonary bypass surgery, cephalothin kinetics before, during, and after (Miller et al), 54
Cardiorespiratory responses to submaximal exercise, effect of marihuana on (Avakian et al), 777
Cardioselective beta adrenoreceptor blocker; kinetics of pamatolol (Carruthers et al), 682
Cardiovascular system, reactivity of, in tetraplegic patient (Sommers), 344
Causation, analysis of, efficacy of different research structures in preventing bias in (Feinstein), 129 (Clinical biostatistics)
Cefamandole kinetics in uremic patients undergoing hemodialysis (Gambertoglio et al), 592
Cephalothin kinetics before, during, and after cardiopulmonary bypass surgery (Miller et al), 54
Cerebrospinal fluid methotrexate kinetics, effect of probenecid on (Howell et al), 641
Children with behavioral disorders and mental illness, plasma chlorpromazine concentrations in (Rivera-Calimlim et al), 114
morphine kinetics in (Dahlström et al), 354
Chlordiazepoxide and oxazepam disposition in cirrhosis (Sellers et al), 240
Chlorimipramine and its demethyl metabolite, plasma levels of, during treatment of depression (Träskman et al), 600
Chlorpromazine concentrations, plasma, in children with behavioral disorders and mental illness (Rivera-Calimlim et al), 114
Cigarette smoking and age, effect of, on antipyrine and indocyanine green elimination (Wood et al), 16
on propranolol disposition (Vestal et al), 8
Cirrhosis, chlordiazepoxide and oxazepam disposition in (Sellers et al), 240
patients with, alterations in disposition of differently cleared drugs in (Klotz et al), 221
Clearance and metabolism, theophylline, effects of allopurinol on (Grygiel et al), 660
Clinical biostatistics. XLVIII. Efficacy of different research structures in preventing bias in analysis of causation (Feinstein), 129
XLIX. Basic data structures used in quantitative indexes (Feinstein), 524
Pharmacology and Therapeutics, American Society for, notes of, 142, 272, 535, 782
Clonidine, reduced renovascular resistance by (Cohen et al), 572
Clorazepate, absorption of desmethyldiazepam from, effect of age and Billroth gastrectomy on (Ochs et al), 449
Cola nut chewing, failure of, to alter antipyrine disposition in normal male subjects from small town in South Central Pennsylvania (Vesell et al), 287

Coronary artery disease, hemodynamic effects of intravenous timolol in (Chew et al), 330
regional effects of propranolol in intraventricular conduction in (Wiener et al), 696
Cumulation factor, drug, two-point determination of, estimation of kinetic parameters from (Bjornsson et al), 540 (Commentary)
kinetics of phenytoin (Allen et al), 445

D

Data structures, basic, used in quantitative indexes (Feinstein), 524 (Clinical biostatistics)
Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians (Woolhouse et al), 584
Degradation, spontaneous, as major mechanism of elimination of melphalan (Alberts et al), 73
Demethylchlorimipramine, plasma protein binding of, techniques for (Bertilsson et al), 265
Demethyl metabolite, chlorimipramine and, plasma levels of, during treatment of depression (Träskman et al), 600
Depression, treatment of, plasma levels of chlorimipramine and its demethyl metabolite during (Träskman et al), 600
Desmethyldiazepam, absorption of, from clorazepate, effect of age and Billroth gastrectomy on (Ochs et al), 449
Dialysis, long-term, patients on, kinetics of intravenous amoxicillin in (Francke et al), 31
2,4-Diamino-N^{10}-methylpteroic acid after high-dose methotrexate (Donehower et al), 63
Diazepam free fraction, inter- and intrasubject variation in (Abel et al), 247
prevents some adverse effects of succinylcholine (Fahmy et al), 395
Diclofenac and naproxen, effect of, on gastroduodenal mucosa (Osnes et al), 399
Dietary fiber (bran), lack of effect of, on digoxin absorption (Woods and Ingelfinger), 21
lipids, carbohydrate, and protein, relative influence of; nutrition and oxidative drug metabolism in man (Anderson et al), 493
Digoxin absorption, lack of effect of bran on (Woods and Ingelfinger), 21
Disopyramide kinetics in patients with acute myocardial infarction (Ilett et al), 1
Disposition, antipyrine, failure of cola nut chewing to alter, in normal male subjects from small town in South Central Pennsylvania (Vesell et al), 287
of differently cleared drugs, alterations in, in patients with cirrhosis (Klotz et al), 221
drug, intraindividual variation in (Alvares et al), 407 (Commentary)
Diuretic, anti-, hormone, syndrome of inappropriate secretion of, haloperidol-induced (Peck and Shenkman), 442
loop, effects of; azosemide (Brater et al), 437
therapy, long-term antihypertensive, effects of atenolol and propranolol when added to (van Rooijen et al), 420
timolol alone and in combination with, treatment with, serum potassium and uric acid changes during (Pedersen and Mikkelsen), 339
Dosage drug, and therapeutic management; how much is enough? (Sicé), 537 (Commentary)
problems, therapeutic, resolving, through dosage forecasting (Sheiner et al), 294
Dosing, long-term, amantadine kinetics in healthy young subjects after (Aoki et al), 729
Drug(s), differently cleared, alterations in disposition of, in patients with cirrhosis (Klotz et al), 221
disposition, intraindividual variation in (Alvares et al), 407 (Commentary)
dosage, and therapeutic management; how much is enough? (Sicé), 537 (Commentary)
metabolism in liver disease; activity of hepatic microsomal metabolizing enzymes (Farrell et al), 483
oxidative, and nutrition in man; relative influence of dietary lipids, carbohydrate, and protein (Anderson et al), 493
Dynamic and kinetic implications of variations in inter- and intrasubject diazepam free fraction (Abel et al), 247

E

Eldery, lorazepam kinetics in (Greenblatt et al), 103
reduced beta adrenoreceptor sensitivity in (Vestal et al), 181
Elimination of naphthoxylactic acid after single and long-term doses of propranolol (Walle et al), 548
saturable presystemic; lorcainide (Jähnchen et al), 187
Enuretic boys, norepinephrine and blood pressure in, effect of imipramine on (Lake et al), 647
Environmental perturbation, variation in drug disposition in relation to (Alvares et al), 407 (Commentary)
Enzyme(s) activity, hepatic drug-metabolizing, and plasma clearance of propranolol and sotalol (Sotaniemi et al), 153
microsomal metabolizing, activity of; drug metabolism in liver disease (Farrell et al), 483
Epilepsy, patients with, plasma renin concentration and phenobarbital levels in (Booker et al), 715

Epileptic, anti-, drug therapy, combined, kinetics and metabolism of carbamazepine during (Eichelbaum et al), 366
Epinephrine, infused, interindividual variation in kinetics of (FitzGerald et al), 669
Erythrocyte, human, lithium uptake by, effect of neuroleptic drugs on (Pandey et al), 96
phenol-O-methyltransferase, inhibition of, in uremia (Pazmiño et al), 464
Estradiol vaginal cream, efficacy of, in postmenopausal women (Dickerson et al), 502
Excretion, renal, and plasma levels of phenytoin and its metabolites in patients with renal failure (Borgå et al), 306
Exercise, effects of atenolol on blood pressure, heart rate, renin, and norepinephrine during (Winer et al), 315
metabolic changes in muscle during, on long-term alprenolol therapy (Frisk-Holmberg et al), 566
submaximal, cardiorespiratory responses to, effect of marihuana on (Avakian et al), 777

F

Fetal, maternal, and neonatal metabolism of lidocaine (Kuhnert et al), 213
Fibrillation and flutter, atrial, verapamil in (Aronow et al), 578
plasma levels and ventricular rate response in patients with (Dominic et al), 710
Fluid volume, hemodynamics, and hypertension, effects of beta blockade with acebutolol on (Dreslinski et al), 562
Flutter and fibrillation, atrial, verapamil in (Aronow et al), 578
plasma levels and ventricular rate response in patients with (Dominic J et al), 710
Foods, methylxanthine-containing, influence of, on theophylline metabolism and kinetics (Monks et al), 513
Forecasting individual pharmacokinetics (Sheiner et al), 294
Furosemide, effect of, on plasma concentration and β-blockade by propranolol (Chiariello et al), 433

G

Gastrectomy, Billroth, and age, effect of, on absorption of desmethyldiazepam from clorazepate (Ochs et al), 449
Gastroduodenal mucosa, effect of diclofenac and naproxen on (Osnes et al), 399
Gestational age and indomethacin elimination in neonate (Evans et al), 746
Glucuronidation of propranolol, presystemic and systemic (Walle et al), 167
Glucuronide, propranolol, cumulation during long-term propranolol therapy; proposed storage mechanism for propranolol (Walle et al), 686

H

Haloperidol-induced syndrome of inappropriate secretio of antidiuretic hormone (Peck and Shenkman), 442
Heart rate, blood pressure, renin, and norepinephrine, effects of atenolol on, during exercise (Winer et al), 315
Hematologic perturbations associated with salicylate (Rothschild), 145 (Commentary)
Hemodialysis, *N*-acetylprocainamide kinetics in functionally anephric patients before and after perturbation by hemodialysis (Stec et al), 618
patients, chronic, kinetics of intravenous mezlocillin in (Francke et al), 228
uremic patients undergoing, cefamandole kinetics in (Gambertoglio et al), 592
Hemodynamic(s) effects of intravenous timolol in coronary artery disease (Chew et al), 330
of oxprenolol and propranolol in hypertension (Franciosa et al), 676
hypertension, and fluid volume, effects of beta blockade with acebutolol on (Dreslinski et al), 562
Hepatic drug-metabolizing enzyme activity and plasma clearance of propranolol and sotalol (Sotaniemi et al), 153
extraction, saturable; lorcainide (Jähnchen et al), 187
metabolism, first-pass, absorption of *d*-propoxyphene modified by (Gram et al), 473
microsomal metabolizing enzymes, activity of; drug metabolism in liver disease (Farrell et al), 483
Hydralazine, patients treated with, identification and quantitation of hydrazine in urine of (Timbrell and Harland), 81
Hydrazine, identification and quantitation of, in urine of patients treated with hydralazine (Timbrell and Harland), 81
Hydrochlorothiazide-induced sympathetic hyperactivity in hypertensive patients (Lake et al), 428
Hydroxylation, debrisoquin, polymorphism among Ghanaians and Caucasians (Woolhouse et al), 584
Hyperactivity, sympathetic, hydrochlorothiazide-induced, in hypertensive patients (Lake et al), 428
Hypertension, hemodynamic(s) effects of oxprenolol and propranolol in (Franciosa et al), 676
and fluid volume, effects of beta blockade with acebutolol on (Dreslinski et al), 562

Hypertension—cont'd
reduced renovascular resistance by clonidine in (Cohen et al), 572
Hypertensive, anti-, diuretic therapy, long-term, effects of atenolol and propranolol when added to (van Rooijen et al), 420
hyperuricemic men, ticrynafen and probenecid in (Peitzman et al), 205
patients, hydrochlorothiazide-induced sympathetic hyperactivity in (Lake et al), 428
influence of prazosin on development of antinuclear antibodies in (Wilson et al), 209
thiazide-resistant, effects of metoprolol on blood pressure and plasma renin activity in (Velasquez et al), 555
Hyperuricemic, hypertensive men, ticrynafen and probenecid in (Peitzman et al), 205
Hypnosedative withdrawal reactions, barbiturate and other, intravenous phenobarbital therapy in; kinetic approach (Martin et al), 256

I

Imipramine, effect of, on norepinephrine and blood pressure in enuretic boys (Lake et al), 647
and trazodone, responses to tyramine and norepinephrine after (Larochelle et al), 24
Indexes, quantitative, basic data structures used in (Feinstein), 524 (Clinical biostatistics)
Indocyanine green and antipyrine elimination, effect of aging and cigarette smoking on (Wood et al), 16
Indomethacin elimination and gestational age in neonate (Evans et al), 746
Intraventricular conduction, regional effects of propranolol in, in coronary artery disease (Wiener et al), 696

K

Kinetic(s), *N*-acetylprocainamide, in functionally anephric patients before and after perturbation by hemodialysis (Stec et al), 618
of acyclovir after intravenous infusion (de Miranda et al), 718
of amantadine in healthy young subjects after long-term dosing (Aoki et al), 729
amikacin, multiple-dose, in pediatric oncology patients (Kramer et al), 635
approach; intravenous phenobarbital therapy in barbiturate and other hypnosedative withdrawal reactions (Martin et al), 256
cefamandole, in uremic patients undergoing hemodialysis (Gambertoglio et al), 592
Kinetic(s)—cont'd
cephalothin; before, during, and after cardiopulmonary bypass surgery (Miller et al), 54
disopyramide, in patients with acute myocardial infarction (Ilett et al), 1
and dynamic implications of variations in inter- and intrasubject diazepam free fraction (Abel et al), 247
of infused epinephrine, interindividual variation in (FitzGerald et al), 669
of intravenous amoxicillin in patients on long-term dialysis (Francke et al), 31
melphalan (Alberts et al), 73
mezlocillin in chronic hemodialysis patients (Francke et al), 228
lorazepam, in elderly (Greenblatt et al), 103
and metabolism of carbamazepine during combined antiepileptic drug therapy (Eichelbaum et al), 366
theophylline, influence of methylxanthine-containing foods on (Monks et al), 513
methotrexate, cerebrospinal fluid, effect of probenecid on (Howell et al), 641
morphine, in children (Dahlström et al), 35
of new antimalarial, mefloquine (Desjardins et al), 372
of oral melphalan (Alberts et al), 737
of pamatolol; cardioselective beta adrenoreceptor blocker (Carruthers et al), 682
parameters, estimation of, from two-point determination of drug cumulation factor (Bjornsson et al), 540 (Commentary)
pharmaco-, forecasting (Sheiner et al), 294
phenytoin cumulation (Allen et al), 445
of piperacillin (Batra et al), 41
of *d*-propoxyphene after single oral and intravenous doses in man (Gram et al), 473
of sulfinpyrazone after intravenous and oral administration (Lecaillon et al), 611
theophylline, effects of three antibiotics on (Pfeifer et al), 36
tobramycin, in morbidly obese patients (Blouin et al), 508
of tolmetin in arthritic patients (Grindel et al), 122
of valproic acid, effects of carbamazepine on, in normal subjects (Bowdle et al), 629

L

Lidocaine, maternal, fetal, and neonatal metabolism of (Kuhnert et al), 213
rectal bioavailability of, in man; partial avoidance of "first-pass" metabolism (de Boer et al), 701
Lipids, carbohydrate, and protein, dietary, relative influence of; nutrition and oxidative drug metabolism in man (Anderson et al), 493

Lithium uptake by human erythrocyte, effect of neuroleptic drugs on (Pandey et al), 96
Liver disease, drug metabolism in; activity of hepatic microsomal metabolizing enzymes (Farrell et al), 483
Loop diuretic, effects of; azosemide (Brater et al), 437
Lorazepam kinetics in elderly (Greenblatt et al), 103
Lorcainide; plasma concentration-effect relationship (Meinertz et al), 196
saturable presystemic elimination (Jähnchen et al), 187

M

Malarial, anti-, new, kinetics of; mefloquine (Desjardins et al), 372
Marihuana, effect of, on cardiorespiratory responses to submaximal exercise (Avakian et al), 777
Maternal, fetal, and neonatal metabolism of lidocaine (Kuhnert et al), 213
Mefloquine; new antimalarial, kinetics of (Desjardins et al), 372
Melphalan, intravenous, kinetics of (Alberts et al), 73
oral, kinetics of (Alberts et al), 737
Menopausal, post-, women, efficacy of estradiol vaginal cream in (Dickerson et al), 502
Mental illness and behavioral disorders, children with, plasma chlorpromazine concentrations in (Rivera-Calimlim et al), 114
Metabolic changes in muscle on long-term alprenolol therapy (Frisk-Holmberg et al), 566
responses to plasma concentrations of theophylline (Cathcart-Rake et al), 89
Metabolism and clearance, theophylline, effects of allopurinol on (Grygiel et al), 660
drug, in liver disease; activity of hepatic microsomal metabolizing enzymes (Farrell et al), 483
method for studying, in populations; racial differences in amobarbital metabolism (Kalow et al), 766
oxidative, and nutrition in man; relative influence of dietary lipids, carbohydrate, and protein (Anderson et al), 493
first-pass, of oxprenolol; hemodynamic effects of oxprenolol and propranolol in hypertension (Franciosa et al), 676
and kinetics of carbamazepine during combined antiepileptic drug therapy (Eichelbaum et al), 366
theophylline, influence of methylxanthine-containing foods on (Monks et al), 513
maternal, fetal, and neonatal, of lidocaine (Kuhnert et al), 213
and protein binding, resultant of; salicylate clearance (Furst et al), 380
Metabolite, demethyl, chlorimipramine and, plasma levels of, during treatment of depression (Träskman et al), 600
Methotrexate, high-dose, presence of 2,4-diamino-N^{10}-methylpteroic acid after (Donehower et al), 63
kinetics, cerebrospinal fluid, effect of probenecid on (Howell et al), 641
Methylprednisolone acetate, rectal and oral absorption of (Garg et al), 232
Methylxanthine-containing foods, influence of, on theophylline metabolism and kinetics (Monks et al), 513
Metolazone therapy, prolonged, in recurrent stone formers, changes in calcium excretion in (Lespier-Dexter and Martinez-Maldonado), 752
Metoprolol, effects of, on blood pressure and plasma renin activity in thiazide-resistant hypertensive patients (Velasquez et al), 555
plasma levels, influence of pentobarbital on (Haglund et al), 326
Mezlocillin, intravenous, kinetics of, in chronic hemodialysis patients (Francke et al), 228
Microsomal metabolizing enzymes, hepatic, activity of; drug metabolism in liver disease (Farrell et al), 483
Model, three-compartment open, of distribution indicated for sulfinpyrazone after intravenous and oral administration (Lecaillon et al), 611
Monitoring, clinical, importance of, with oral melphalan (Alberts et al), 737
drug dosage and therapeutic management; how much is enough? (Sicé), 537 (Commentary)
of lorcainide by following ECG (Meinertz et al), 196
Morphine kinetics in children (Dahlström et al), 354
Mucosa, gastroduodenal, effect of diclofenac and naproxen on (Osnes et al), 399
Muscle, metabolic changes in, on long-term alprenolol therapy (Frisk-Holmberg et al), 566
Myocardial infarction, acute, patients with, disopyramide kinetics in (Ilett et al), 1

N

Nadolol and propranolol, equiblocking doses of, effects of, on left ventricular performance (Le Winter et al), 162
Naphthoxylactic acid after single and long-term doses of propranolol (Walle et al), 548
Naproxen and diclofenac, effect of, on gastroduodenal mucosa (Osnes et al), 399
Nefopam, effects of, on visual tracking (Belleville et al), 457

Neonatal, fetal, and maternal metabolism of lidocaine (Kuhnert et al), 213
Neonate, gestational age and indomethacin elimination in (Evans et al), 746
Neuroleptic drugs, effect of, on lithium uptake by human erythrocyte (Pandey et al), 96
Norepinephrine and blood pressure in enuretic boys, effect of imipramine on (Lake et al), 647
renin, heart rate, and blood pressure, effects of atenolol on, during exercise (Winer et al), 315
and tyramine, responses to, after imipramine and trazodone (Larochelle et al), 24
Nutrition and oxidative drug metabolism in man; relative influence of dietary lipids, carbohydrate, and protein (Anderson et al), 493

O

Obese patients, morbidly, tobramycin kinetics in (Blouin et al), 508
Oncology patients, pediatric, multiple-dose amikacin kinetics in (Kramer et al), 635
Oxazepam and chlordiazepoxide disposition in cirrhosis (Sellers et al), 240
Oxidative drug metabolism and nutrition in man; relative influence of dietary lipids, carbohydrate, and protein (Anderson et al), 493
Oxprenolol and propranolol, hemodynamic effects of, in hypertension (Franciosa et al), 676

P

Pamatolol kinetics; cardioselective beta adrenoreceptor blocker (Carruthers SG et al), 682
Parameters, kinetic, estimation of, from two-point determination of drug cumulation factor (Bjornsson et al), 540 (Commentary)
Patent ductus arteriosus, treatment of, and indomethacin (Evans et al), 746
Pediatric oncology patients, multiple-dose amikacin kinetics in (Kramer et al), 635
Pentobarbital, influence of, on metoprolol plasma levels (Haglund et al), 326
Pharmacokinetics, individual, forecasting (Sheiner et al), 294
Pharmacology, clinical, antipyrine test in; conceptions and misconceptions (Vesell), 275 (Commentary)
and Therapeutics, Clinical, American Society for, notes of, 142, 272, 535, 782
Phenobarbital levels and plasma renin concentration in patients with epilepsy (Booker et al), 715
therapy, intravenous, in barbiturate and other hypnosedative withdrawal reactions; kinetic approach (Martin et al), 256
Phenol-O-methyltransferase, human erythrocyte, inhibition of, in uremia (Pazmiño et al), 464
Phenotype, acetylator, screening methods using sulfamethazine for determining (du Souich et al), 757
Phenytoin cumulation kinetics (Allen et al), 445
and its metabolites, plasma levels and renal excretion of, in patients with renal failure (Borgå et al), 306
Piperacillin kinetics (Batra et al), 41
Plasma chlorpromazine concentrations in children with behavioral disorders and mental illness (Rivera-Calimlim et al), 114
clearance of propranolol and sotalol and hepatic drug-metabolizing enzyme activity (Sotaniemi et al), 153
concentration and β-blockade by propranolol, effect of furosemide on (Chiariello et al), 433
-effect relationship; lorcainide (Meinertz et al), 196
of theophylline, metabolic responses to (Cathcart-Rake et al), 89
levels of chlorimipramine and its demethyl metabolite during treatment of depression (Träskman et al), 600
metoprolol, influence of pentobarbital on (Haglund et al), 326
and renal excretion of phenytoin and its metabolites in patients with renal failure (Borgå et al), 306
protein binding of demethylchlorimipramine, techniques for (Bertilsson et al), 265
renin activity and blood pressure, effects of metoprolol on, in thiazide-resistant hypertensive patients (Velasquez et al), 555
concentration and phenobarbital levels in patients with epilepsy (Booker et al), 715
theophylline levels after sustained-release aminophylline (Trembath et al), 654
Polymorphism, debrisoquin hydroxylation, among Ghanaians and Caucasians (Woolhouse et al), 584
Populations, method for studying drug metabolism in; racial differences in amobarbital metabolism (Kalow et al), 766
Potassium, serum, and uric acid changes during treatment with timolol alone and in combination with diuretic (Pedersen and Mikkelsen), 339
Prazosin, influence of, on development of antinuclear antibodies in hypertensive patients (Wilson et al), 209
Probenecid, effects of, on cerebrospinal fluid methotrexate kinetics (Howell et al), 641
and ticrynafen in hyperuricemic, hypertensive men (Peitzman et al), 205
d-Propoxyphene kinetics after single oral and intravenous doses in man (Gram et al), 473

Propranolol and atenolol, effects of, when added to long-term antihypertensive diuretic therapy (van Rooijen et al), 420
disposition, effects of age and cigarette smoking on (Vestal et al), 8
glucuronide cumulation during long-term propranolol therapy; proposed storage mechanism for propranolol (Walle et al), 686
and nadolol, equiblocking doses of, effects of, on left ventricular performance (Le Winter et al), 162
and oxprenolol, hemodynamic effects of, in hypertension (Franciosa et al), 676
plasma concentration and β-blockade by, effect of furosemide on (Chiariello et al), 433
presystemic and systemic glucuronidation of (Walle et al), 167
radioreceptor assay for (Bilezikian et al), 173
regional effects of, in intraventricular conduction in coronary artery disease (Wiener et al), 696
single and long-term doses of, naphthoxylactic acid after (Walle et al), 548
and sotalol, plasma clearance of, and hepatic drug-metabolizing enzyme activity (Sotaniemi et al), 153
Protein binding and metabolism, resultant of; salicylate clearance (Furst et al), 380
plasma, of demethylchlorimipramine, techniques for (Bertilsson et al), 265
carbohydrate, and lipids, dietary, relative influence of; nutrition and oxidative drug metabolism in man (Anderson et al), 493

Q

Quantitative indexes, basic data structures used in (Clinical biostatistics) (Feinstein), 524

R

Racial differences in amobarbital metabolism; method for studying drug metabolism in populations (Kalow et al), 766
Radioreceptor assay for propranolol (Bilezikian et al), 173
Reactivity of cardiovascular system in tetraplegic patient (Sommers), 344
Rectal bioavailability of lidocaine in man; partial avoidance of "first-pass" metabolism (de Boer et al), 701
Regional effects of propranolol in intraventricular conduction in coronary artery disease (Wiener et al), 696
Renal failure, patients with, plasma levels and renal excretion of phenytoin and its metabolites in (Borgå et al), 306
Renin, heart rate, blood pressure, and norepinephrine, effects of, during exercise (Winer et al), 315
Renovascular resistance, reduced, by clonidine (Cohen et al), 572
Research structures, different, efficacy of, in preventing bias in analysis of causation (Feinstein), 129 (Clinical biostatistics)

S

Salicylate clearance, resultant of protein binding and metabolism (Furst et al), 380
hematologic perturbations associated with (Rothschild), 145 (Commentary)
Screening methods using sulfamethazine for determining acetylator phenotype (du Souich et al), 757
Secretion, inappropriate, of antidiuretic hormone, syndrome of, haloperidol-induced (Peck and Shenkman), 442
Serum calcium, effect of thiazides on (Mohamadi et al), 390
potassium and uric acid changes during treatment with timolol alone and in combination with diuretic (Pedersen and Mikkelsen), 339
Smoking, cigarette, and age, effect of, on antipyrine and indocyanine green elimination (Wood et al), 16
on propranolol disposition (Vestal et al), 8
Sotalol and propranolol, plasma clearance of, and hepatic drug-metabolizing enzyme activity (Sotaniemi et al), 153
Stone formers, recurrent, changes in calcium excretion after prolonged metolazone therapy in (Lespier-Dexter and Martinez-Maldonado), 752
Storage mechanism, proposed, for propranolol; propranolol glucuronide cumulation during long-term propranolol therapy (Walle et al), 686
Succinylcholine, some adverse effects of, prevented by diazepam (Fahmy et al), 395
Sulfamethazine, screening methods using, for determining acetylator phenotype (du Souich et al), 757
Sulfinpyrazone kinetics after intravenous and oral administration (Lecaillon et al), 611
Sustained-release aminophylline, plasma theophylline levels after (Trembath et al), 654
Sympathetic activity, correlation of plasma norepinephrine with (FitzGerald et al), 669
hyperactivity, hydrochlorothiazide-induced, in hypertensive patients (Lake et al), 428
Sympathomimetic component of oxprenolol; hemodynamic effects of oxprenolol and propranolol in hypertension (Franciosa et al), 676
Syndrome of inappropriate secretion of antidiuretic hormone, haloperidol-induced (Peck and Shenkman), 442

T

Test, antipyrine, in clinical pharmacology; conceptions and misconceptions (Vesell), 275 (Commentary)
Tetraplegic patient, reactivity of cardiovascular system in (Sommers), 344
Theophylline kinetics, effects of three antibiotics on (Pfeifer et al), 36
levels, plasma, after sustained-release aminophylline (Trembath et al), 654
metabolism and clearance, effects of allopurinol on (Grygiel et al), 660
and kinetics, influence of methylxanthine-containing foods on (Monks et al), 513
plasma concentrations of, metabolic responses to (Cathcart-Rake et al), 89
Therapeutics, American Society for Clinical Pharmacology and, notes of, 142, 272, 535, 782
Thiazide(s), effect of, on serum calcium (Mohamadi et al), 390
-resistant hypertensive patients, effects of metoprolol on blood pressure and plasma renin activity in (Velasquez et al), 555
Ticrynafen and probenecid in hyperuricemic, hypertensive men (Peitzman et al), 205
Timolol alone and in combination with diuretic, treatment with, serum potassium and uric acid changes during (Pedersen and Mikkelsen), 339
intravenous, hemodynamic effects of, in coronary artery disease (Chew et al), 330
Tobramycin kinetics in morbidly obese patients (Blouin et al), 508
Tolmetin, absorption and excretion of, in arthritic patients (Grindel et al), 122
Tracking, visual, effects of nefopam on (Belleville et al), 457
Trazodone and imipramine, responses to tyramine and norepinehrine after (Larochelle et al), 24
Tubular secretion process, saturation of, at high piperacillin concentrations in serum (Batra et al), 41
Tumor, anti-, activity, altered, following formation of 2,4-diamino-N^{10}-methylpteroic acid through methotrexate metabolism (Donehower et al), 63
Tyramine and norepinephrine, responses to, after imipramine and trazodone (Larochelle et al), 24

U

Uremia, human phenol-O-methyltransferase in, inhibition of (Pazmiño et al), 464
Uremic patients undergoing hemodialysis, cefamandole kinetics in (Gambertoglio et al), 592
Uric acid and serum potassium changes during treatment with timolol alone and in combination with diuretic (Pedersen and Mikkelsen), 339
Urine, hydrazine in, identification and quantitation of, of patients treated with hydralazine (Timbrell and Harland) 81

V

Vaginal cream, estradiol, efficacy of, in postmenopausal women (Dickerson et al), 502
Valproic acid kinetics, effects of carbamazepine on, in normal subjects (Bowdle et al), 629
Variation, inter- and intrasubject, in diazepam free fraction (Abel et al), 247
intraindividual, in drug disposition (Alvares et al), 407 (Commentary)
Ventricular, left, performance, effects of equiblocking doses of nadolol and propranolol on (Le Winter et al), 162
rate response and verapamil plasma levels in patients with atrial fibrillation and flutter (Dominic et al), 710
Verapamil in atrial fibrillation and atrial flutter (Aronow et al), 578
plasma levels and ventricular rate response in patients with atrial fibrillation and flutter (Dominic et al), 710
Viral, anti-, drug (acyclovir) after intravenous infusion (de Miranda et al), 718
Visual tracking, effects of nefopam on (Belleville et al), 457

W

Withdrawal reactions, barbiturate and other hypnosedative, intravenous phenobarbital therapy in; kinetic approach (Martin et al), 256